UK MHRA approves Vertex’s Alyftrek, a once-daily next-in-class CFTR modulator to treat cystic fibrosis: London Monday, March 10, 2025, 10:00 Hrs [IST] Vertex Pharmaceuticals, a ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Vertex announced that the United Kingdom Medicines and Healthcare products Regulatory Agency has granted approval for ALYFTREK, a once-daily ...

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has today approved Alyftrek (triple combination medicine ...

Vertex Pharmaceuticals (NasdaqGS:VRTX) announced that its cystic fibrosis treatment, ALYFTREK®, had received regulatory approval from the UK's MHRA, a significant milestone in expanding its market ...

The agency approved it based on two Phase III studies showing the drug to be as effective as another combination therapy at improving lung function.

However, Vertex remains an attractive stock. Since that setback, the biotech has earned approval for Alyftrek, a next-generation medicine in its core area of expertise, cystic fibrosis (CF).

Growth is expected from U.S. launches of ALYFTREK and JOURNAVX, along with the continued ramp of CASGEVY globally. JOURNAVX is anticipated to contribute more significantly in the second half of ...

Alyftrek's launch is considered the second most crucial factor for Vertex's stock performance in 2025, following Journavx. Management has noted early interest from three groups of potential ...

Vertex Pharmaceuticals Incorporated ( NASDAQ: VRTX) TD Cowen 45th Annual Health Care Conference Transcript March 3, 2025 3:10 PM ET David Altshuler - Executive Vice President, Global Research and CSO ...

We appreciate that Vertex is using its healthy cash flows from its CF franchise to expand its portfolio, and is focused on delivering strong commercial launches of Alyftrek and Journavx.